EUVIMEDEUVIMED entdecken
Crossref

Proton-Based Radiation Therapy for Skull Base Chondrosarcomas in Children and Adolescents: 40-Year Experience From the Massachusetts General Hospital

Myrsini Ioakeim-Ioannidou, Saveli Goldberg, Tobias Urell, Athena Tejada, G Petur Nielsen, Yin P Hung, Judith Adams, Barbara Fullerton, Paul Caruso, Manuel Patino, Karen Buch, Sandra Rincon und 7 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2024.09.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Myrsini Ioakeim-Ioannidou und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiotherapy, School o…. Hauptthemen laut MEDLINE: Proton Therapy, Skull Base Neoplasms, Chondrosarcoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The literature on skull base chondrosarcoma (CHS) is scarce. We report outcomes for pediatric and young patients ≤22 years with base of skull CHSs treated with proton-based radiation therapy (PBRT). METHODS AND MATERIALS: We retrospectively reviewed all patients treated with PBRT between 1981 and 2023. Primary endpoints were overall survival (OS), chondrosarcoma-specific survival (CSS), progression-free survival (PFS), local control, and distal control. RESULTS: Eighty-four patients were identified. Median age at diagnosis was 19 years (range, 6-22). Most patients (n = 79, 94%) had conventional CHS, whereas 5 (6%) had mesenchymal CHS. Nine patients (11%) underwent gross total resection, 64 (76%) subtotal resection, and 11 patients (13%) underwent biopsy. Twenty-four (29%) patients progressed before radiation therapy. The median prescription dose was 70 Gy (relative biological equivalent) (range, 50-79.7). At a median follow-up of 18.0 years (IQR, 9.2-26.2) from diagnosis, 11 patients recurred (7 local, 4 distant). Six patients died of disease. Five patients died of other causes. Ten-year OS, CSS, and PFS rates for all patients were 93.3%, 94.7%, and 88%, respectively. Twenty-year OS, CSS, and PFS rates for conventional CHS (n = 79) were 93.1%, 97.1%, and 89.2%, respectively. Mesenchymal histology was significantly associated with worse OS and PFS. Preradiation therapy tumor progression portended worse OS and CSS. Eight patients (9.9 %) experienced a late toxicity grade 3 or greater. CONCLUSIONS: This is the largest cohort of pediatric base of skull CHSs in literature to date. High-dose PBRT after surgical resection achieves excellent disease control with minimal toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton TherapySkull Base NeoplasmsChondrosarcomaHumansChildAdolescentMaleFemaleRetrospective StudiesYoung AdultProgression-Free SurvivalRadiotherapy Dosage

Autor:innen und Institutionen

  • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece.
  • Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Deparment of Neuro-radiology, Lenox Hill Radiology and Medical Imaging Associates, New York, New York.
  • Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
  • Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece.

Zitieren

APA

Ioakeim-Ioannidou, M., Goldberg, S., Urell, T., Tejada, A., Nielsen, G. P., Hung, Y. P., Adams, J., Fullerton, B., Caruso, P., Patino, M., Buch, K., Rincon, S., Sakai, O., Tolia, M., Ebb, D., Cote, G., Curry, W., Giantsoudi, D., & MacDonald, S. M. (2025). Proton-Based Radiation Therapy for Skull Base Chondrosarcomas in Children and Adolescents: 40-Year Experience From the Massachusetts General Hospital. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.09.030

Vancouver

Ioakeim-Ioannidou M, Goldberg S, Urell T, Tejada A, Nielsen GP, Hung YP, et al. Proton-Based Radiation Therapy for Skull Base Chondrosarcomas in Children and Adolescents: 40-Year Experience From the Massachusetts General Hospital. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2024.09.030

BibTeX
@article{IoakeimIoannidou2025,
  author = {Ioakeim-Ioannidou, Myrsini and Goldberg, Saveli and Urell, Tobias and Tejada, Athena and Nielsen, G Petur and Hung, Yin P and Adams, Judith and Fullerton, Barbara and Caruso, Paul and Patino, Manuel and Buch, Karen and Rincon, Sandra and Sakai, Osamu and Tolia, Maria and Ebb, David and Cote, Gregory and Curry, William and Giantsoudi, Drosoula and MacDonald, Shannon M},
  title = {Proton-Based Radiation Therapy for Skull Base Chondrosarcomas in Children and Adolescents: 40-Year Experience From the Massachusetts General Hospital},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2024.09.030}
}
Kostenlos starten →